Mosaic ImmunoEngineering Inc. (CPMV): R&D Expense
$64.0K
Year ended 2025-12-31
$63.7K
Trailing 12 months to 2026-06-30
-60.6%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $64.0K | -65.2% | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | $183.9K | -57.8% | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | $435.4K | -58.5% | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | $1.05M | -28.0% | 2024-04-15, From 2022-01-01 |
| 2021-12-31 | $1.46M | n/a | 2023-03-02, From 2021-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Mosaic ImmunoEngineering Inc. (CPMV) | 2025-12-31 | $64.0K | -65.2% |
| Agentix Corp. (AGTX) | 2026-03-31 | $125.1K | -30.9% |
| Liminatus Pharma, Inc. (LIMN) | 2024-12-31 | $2.69M | n/a |
| Adaptin Bio, Inc. (APTN) | 2025-12-31 | $1.77M | -2.8% |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 2025-12-31 | $4.17M | -10.2% |
| Abpro Holdings, Inc. (ABPO) | 2025-12-31 | $989.0K | -66.8% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $100.0K | -39.0% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $3.13M | +127.7% |
| Estrella Immunopharma, Inc. (ESLA) | 2025-12-31 | $10.25M | n/a |
Compare CPMV, AGTX, LIMN, APTN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗